Mecoson Labs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 6 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue -22.16%
(FY 2023)
- Profit 14205.13%
(FY 2023)
- Ebitda 67.52%
(FY 2023)
- Net Worth 119.39%
(FY 2023)
- Total Assets 40.21%
(FY 2023)
About Mecoson Labs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rohit Dobariya and Yogesh Panchal serve as directors at the Company.
- CIN/LLPIN
U51909GJ2018PTC105453
- Company No.
105453
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Dec 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surat, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Mecoson Labs Private Limited offer?
Mecoson Labs Private Limited offers a wide range of products and services, including Cosmetics, Hair & Beauty Products, Body Cream, Anti Infective Drugs & Medicines, Antibacterial Drugs, Antifungal Cream, Ointment & Powder, Pain Relief Drugs & Pharmaceuticals, Diclofenac, Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, Nutraceuticals & Dietary Supplements.
Who are the key members and board of directors at Mecoson Labs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Yogesh Panchal  | Director | 10-Mar-2021 | Current |
| Rohit Dobariya | Director | 05-Dec-2018 | Current |
Financial Performance of Mecoson Labs.
Mecoson Labs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 22.16% decrease. The company also saw a substantial improvement in profitability, with a 14205.13% increase in profit. The company's net worth Soared by an impressive increase of 119.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mecoson Labs?
In 2023, Mecoson Labs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
_PRIVATE_LIMITED.webp)
Sarvasya Trading (India) Private LimitedActive 7 years 4 monthsRohit Dobariya and Yogesh Panchal are mutual person
Mecoson Pharmaceuticals Private LimitedActive 4 years 3 monthsRohit Dobariya and Yogesh Panchal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mecoson Labs?
Unlock and access historical data on people associated with Mecoson Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mecoson Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mecoson Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
